Generation Bio News
News
0
Ticker
GBIO
ISIN
US37148K2096
Generation Bio Eulerpool News
Generation Bio Stock News
Generation Bio is being monitored by journalists and investors worldwide. We gather the latest Generation Bio news here.
- December 15·Benzinga
- December 15·Benzinga
- December 2·Yahoo
- November 5·Yahoo
- October 22·Yahoo
- August 13·Yahoo
- August 13·Benzinga
- August 12·Benzinga
- August 12·Benzinga
- July 18·Yahoo
- June 25·Yahoo
- May 28·Yahoo
- May 7·Yahoo
- April 2·Yahoo
- March 13·Yahoo
- January 23·Yahoo
- January 16·Yahoo
- January 6·Yahoo
- December 2·Yahoo
- November 10·Yahoo
Generation Bio Stock Press Releases
Generation Bio regularly publishes news on the company's website that are relevant for investors.
- January 3•Generation Bio
- November 3•Generation Bio
- September 22•Generation Bio
- September 20•Generation Bio
- August 4•Generation Bio
- August 2•Generation Bio
- July 18•Generation Bio
- June 21•Generation Bio
- June 2•Generation Bio
- May 5•Generation Bio
- April 5•Generation Bio
- March 2•Generation Bio
- February 24•Generation Bio
- February 10•Generation Bio
- January 5•Generation Bio
- December 14•Generation Bio
- November 10•Generation Bio
- October 22•Generation Bio
- October 21•Generation Bio
- October 15•Generation Bio
- August 11•Generation Bio
- August 3•Generation Bio
- July 14•Generation Bio
- July 8•Generation Bio
- June 9•Generation Bio
- May 27•Generation Bio
- May 12•Generation Bio
- April 27•Generation Bio
- April 8•Generation Bio
- March 18•Generation Bio
Generation Bio News 2026
This page contains all current news, analysis and press releases for Generation Bio stock (GBIO, ISIN: US37148K2096). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Generation Bio.
Generation Bio Stock
Generation Bio Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate.